Vestcor Inc Sells 5,568 Shares of Encompass Health Corporation $EHC

Vestcor Inc reduced its position in Encompass Health Corporation (NYSE:EHC) by 6.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,345 shares of the company’s stock after selling 5,568 shares during the quarter. Vestcor Inc owned 0.08% of Encompass Health worth $8,528,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in Encompass Health by 21.5% in the first quarter. Royal Bank of Canada now owns 88,470 shares of the company’s stock worth $8,960,000 after purchasing an additional 15,677 shares in the last quarter. Millennium Management LLC raised its holdings in Encompass Health by 38.4% in the first quarter. Millennium Management LLC now owns 92,197 shares of the company’s stock worth $9,338,000 after purchasing an additional 25,574 shares in the last quarter. Caxton Associates LLP bought a new position in Encompass Health in the first quarter worth about $259,000. Walleye Capital LLC raised its holdings in Encompass Health by 667.6% in the second quarter. Walleye Capital LLC now owns 6,522 shares of the company’s stock worth $800,000 after purchasing an additional 7,671 shares in the last quarter. Finally, Gamco Investors INC. ET AL bought a new position in Encompass Health in the second quarter worth about $588,000. 97.25% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. TD Cowen assumed coverage on shares of Encompass Health in a report on Thursday, May 28th. They issued a “buy” rating and a $125.00 target price for the company. Leerink Partners set a $152.00 target price on shares of Encompass Health in a report on Friday, May 22nd. Barclays reduced their target price on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a report on Tuesday, May 5th. Finally, Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $143.86.

Encompass Health Price Performance

Shares of EHC stock opened at $104.39 on Friday. Encompass Health Corporation has a fifty-two week low of $92.77 and a fifty-two week high of $127.99. The firm has a market capitalization of $10.36 billion, a price-to-earnings ratio of 17.43, a PEG ratio of 2.18 and a beta of 0.72. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.17 and a current ratio of 1.17. The stock’s 50-day simple moving average is $103.79 and its 200-day simple moving average is $105.01.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Thursday, April 30th. The company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.51 by $0.09. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the firm earned $1.37 earnings per share. The company’s revenue was up 9.0% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. As a group, equities analysts forecast that Encompass Health Corporation will post 5.97 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Wednesday, July 1st will be paid a dividend of $0.19 per share. The ex-dividend date is Wednesday, July 1st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s payout ratio is presently 12.69%.

Insider Transactions at Encompass Health

In other news, EVP Patrick William Tuer sold 682 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $104.56, for a total transaction of $71,309.92. Following the sale, the executive vice president owned 24,755 shares in the company, valued at approximately $2,588,382.80. The trade was a 2.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Treasurer Edmund Fay sold 11,937 shares of the business’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $107.00, for a total value of $1,277,259.00. Following the sale, the treasurer owned 89,325 shares in the company, valued at $9,557,775. The trade was a 11.79% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.80% of the stock is currently owned by insiders.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.